| [1] |
POLLYEA D A, ALTMAN J K, ASSI R, et al. Acute myeloid leukemia,version 3.2023,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2023, 21(5):503-513.
DOI
URL
|
| [2] |
SCHUH A C. Timely diagnosis and treatment of acute promyelocytic leukemia should be available to all[J]. Haematologica, 2022, 107(3):570-571.
DOI
URL
|
| [3] |
NI X, HU G, CAI X. The success and the challenge of all-trans retinoic acid in the treatment of cancer[J]. Crit Rev Food Sci Nutr, 2019, 59(1):S71-S80.
DOI
URL
|
| [4] |
MA Y F, LU Y, WU Q, et al. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia[J]. J Hematol Oncol, 2022, 15(1): 148.
DOI
|
| [5] |
MCDONNELL M H, SMITH E T Jr, LIPFORD E H, et al. Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype[J]. Hematol Oncol Stem Cell Ther, 2017, 10(1):35-38.
DOI
PMID
|
| [6] |
KRISHNAMURTHY K, CHOUDHURI J, RAMESH K H, et al. MPO expression of background neutrophils in mpo negative acute promyelocytic leukemia,an easy clue to corroborate a challenging diagnosis:a case report and review of literature[J]. Case Rep Hematol, 2023, 2023:7979261.
|
| [7] |
MO X, CHEN H. Acute promyelocytic leukaemia with myeloperoxidase-negative rectangular inclusions[J]. Br J Haematol, 2020, 188(1):8.
DOI
URL
|
| [8] |
GLEGHORN D M, THOMAS W. Prevalence of myeloperoxidase deficiency determined using an ADVIA 2120i[J]. Int J Lab Hematol, 2020, 42(5):e220-e223.
|
| [9] |
HEIBLIG M, PAUBELLE E, PLESA A, et al. Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia[J]. Blood, 2017, 129(1):128-131.
DOI
PMID
|
| [10] |
ROMANI C, MURRU R, PETTINAU M, et al. A case of fatal overwhelming microgranular variant(M3v)of acute promyelocytic leukemia with extensive extramedullary involvement[J]. Int J Hematol, 2010, 91(3):551-552.
DOI
URL
|
| [11] |
ZHANG X, SUN J, YU W, et al. Current views on the genetic landscape and management of variant acute promyelocytic leukemia[J]. Biomark Res, 2021, 9(1):33.
DOI
PMID
|
| [12] |
ZHANG X W, YAN X J, ZHOU Z R, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML[J]. Science, 2010, 328(5975):240-243.
DOI
URL
|
| [13] |
KOZONO S, LIN Y M, SEO H S, et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells[J]. Nat Commun, 2018, 9(1):3069.
DOI
PMID
|
| [14] |
LI Y, MA X, CHEN Z, et al. B1 oligomerization regulates PML nuclear body biogenesis and leukemogenesis[J]. Nat Commun, 2019, 10(1):3789.
DOI
PMID
|
| [15] |
LI Y, MA X, WU W, et al. PML nuclear body biogenesis,carcinogenesis,and targeted therapy[J]. Trends Cancer, 2020, 6(10):889-906.
DOI
URL
|
| [16] |
LI Y, MA X, MENG G. PML nuclear body biogenesis and oligomerization-driven leukemogenesis[J]. Blood Sci, 2020, 2(1):7-10.
DOI
PMID
|
| [17] |
LALLEMAND-BREITENBACH V, DE THÉ H. PML nuclear bodies[J]. Cold Spring Harb Perspect Biol, 2010, 2(5):a000661.
|
| [18] |
WANG P, BENHENDA S, WU H, et al. RING tetramerization is required for nuclear body biogenesis and PML sumoylation[J]. Nat Commun, 2018, 9(1):1277.
DOI
PMID
|
| [19] |
VERMA S, SINGHAL P, SINGH S, et al. Atypical morphology and aberrant immunophenotypic expression:a diagnostic dilemma in acute promyelocytic leukemia[J]. J Appl Hematol, 2022, 13(1):63-67.
DOI
URL
|
| [20] |
FANG H, WANG S A, HU S, et al. Acute promyelocytic leukemia:immunophenotype and differential diagnosis by flow cytometry[J]. Cytometry B Clin Cytom, 2022, 102(4):283-291.
DOI
URL
|
)
